Intuitive Surgical's Shares Soared 9.34% After Earnings Release: Unveiling the Competitive Advantages of the Medical Robot Star
Second quarter revenue of $2.01 billion increased by 14% compared with $1.76 billion in the second quarter of 2023. The second quarter GAAP net income attributable to Intuitive was $527 million, or $1.46 per diluted share, compared with $421 million, or $1.18 per diluted share, in the second quarter of 2023.
Saudi Arabia Disposable Endoscopy Devices Market Competition, Forecast & Opportunities 2024-2029 Featuring Ambu, Abdulrehman Algosaibi (Hill-Rom), Boston Scientific, Coloplast, and Gulf Medical
Tesla, AT&T, Alphabet, Chipotle, Visa, and More Stocks to Watch This Week
Second-quarter earnings season continues with Verizon, Alphabet, Coca-Cola, Comcast, General Motors, Tesla, Visa, AT&T, Chipotle, and Newmont.
Unusual Options Activity: GOOGL, FITB and Others Attract Market Bets, GOOGL V/OI Ratio Reaches 63.9
EST Jul 19th Afternoon Delivery - In the last two hours of trading, 6 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Behind the Scenes of Boston Scientific's Latest Options Trends
Whales with a lot of money to spend have taken a noticeably bullish stance on Boston Scientific.Looking at options history for Boston Scientific (NYSE:BSX) we detected 16 trades.If we consider the
Boston Scientific on Pace for Largest Percent Decrease Since October 2023 -- Data Talk
Boston Scientific Corporation (BSX) is currently at $74.40, down $3.01 or 3.89% --Would be lowest close since May 23, 2024, when it closed at $74.38 --On pace for largest percent decrease since Oct. 1
Med-tech and Healthcare Stocks With Upside During 2Q Earnings - Baird
Least Shorted S&P 500 Stocks in June
Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June
Express News | TD Cowen Maintains Buy on Boston Scientific, Raises Price Target to $86
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
Boston Scientific Is Maintained at Buy by Truist Securities
Boston Scientific Is Maintained at Buy by Truist
Indonesia Medical Devices Industry Research Report 2024-2033 Featuring Medtronic, Becton Dickinson, Johnson & Johnson, Siemens Healthineers, Philips Healthcare, GE Healthcare, & Boston Scientific
TD Cowen Adjusts Price Target on Boston Scientific to $86 From $77
Boston Scientific (BSX) has an average rating of buy and price targets ranging from $70 to $100, according to analysts by Capital IQ.Price: 78.45, Change: +0.43, Percent Change: +0.55
A Quick Look at Today's Ratings for Boston Scientific(BSX.US), With a Forecast Between $84 to $92
On Jul 16, major Wall Street analysts update their ratings for $Boston Scientific(BSX.US)$, with price targets ranging from $84 to $92.Morgan Stanley analyst Patrick Wood maintains with a buy rating,
Express News | Boston Scientific Corp : TD Cowen Raises Target Price to $86 From $77
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
Critical Insights From Boston Scientific Analyst Ratings: What You Need To Know
In the last three months, 21 analysts have published ratings on Boston Scientific (NYSE:BSX), offering a diverse range of perspectives from bullish to bearish.In the table below, you'll find a
Boston Scientific Is Maintained at Overweight by Morgan Stanley
Boston Scientific Is Maintained at Overweight by Morgan
Boston Scientific Hits All-time High